

From: Mackey, James
To: AGO - High Cost Prescription Drugs
Cc: Fitzsimmons, Tricia; Angulo, Rafael; Nussbaum, Brett; Villiger, Nancy; Naidus, Bob
Subject: Notice of Introduction of New High-Cost Prescription Drugs - Attorney General's Office state of Vermont
Date: Wednesday, October 9, 2019 5:39:51 PM

Attorney General's Office state of Vermont:

Pursuant to 18 V.S.A. § 4637 (Notice of Introduction of New High-Cost Prescription Drugs), effective July 1, 2018, when a prescription drug manufacturer introduces a new prescription drug to market at a wholesale acquisition price above the threshold set for a specialty drug under the Medicare Part D program, that manufacturer is required to provide certain written information to the Attorney General's Office.

Per section (2) (b) of the § 4637. Notice Of Introduction Of New High-Cost Prescription Drugs, Novartis is notifying Office of the Attorney General in the state of Vermont the Wholesaler Acquisition Cost (WAC) within 3 calendar days following the release of BEOVU® to the commercial market. See table below:

Product Name	NDC	DRUG_PROD_DESC	INTRODUCED_TO_MARKET_DATE	WAC_AT_INTRODUCTION
BEOVU® (brolicizumab-dbil)	0078-0827-61	BEOVU® (brolicizumab-dbil) is a human vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of Neovascular (Wet) Age-Related Macular Degeneration (AMD). BEOVU® is administered by injection and available by prescription only. BEOVU® injection is a sterile, preservative-free, clear to slightly opalescent, colorless to slightly brownish-yellow solution in a single-dose vial for intravitreal administration. Each vial is designed to deliver 0.05 mL of solution containing 6 mg brolicizumab-dbil, polysorbate 80 (0.02%), sodium citrate (10 mM), sucrose (5.8%), and Water for Injection, USP and with a pH of approximately 7.2.	10.8.2019	\$1,850

Novartis appreciates the opportunity to respond to this request. **Please confirm receipt and acceptance of the above information.** If you have any questions, please feel free to contact me.

James Mackey
Associate Director, Government Pricing

Phone +1 962 289 4526
james.mackey@novartis.com

Managed Markets Finance/HCA
Novartis Pharmaceuticals
One Health Plaza
East Hanover, NJ 07936-1080
USA